In recent years, significant steps have been taken to improve patient access to Comprehensive Genomic Profiling (CGP) in Europe, however today the full benefits are not yet realised.
Access to CGP in Europe is limited, with European cancer patients not having access to potentially life-changing targeted cancer treatments because current funding and reimbursement frameworks do not allow for routine testing for all relevant cancer mutations.
To address this, the multistakeholder European Coalition for Comprehensive Genomic Profiling (ECGP), made up of patients, clinicians, pathologists and industry, is publishing recommendations describing the value of CGP, and strategies for decision-makers to improve patient access to CGP.
The overall objective is to overcome implementation barriers and thus increase patients’ access to CGP. ECGP’s recommendations highlight the critical role of genomic technologies, ideal policy frameworks, and collaborative efforts that can accelerate the adoption of personalised medicine in Europe.
What are ECGP’s recommendations:
- CGP enables the selection of appropriate treatment options for patients when available, thereby avoiding the use of less suitable treatments.
- Swift adoption of CGP requires clear funding and reimbursement pathways, both of which are currently lacking.
- Optimal implementation of CGP requires inclusion in guidelines, enhanced (data) infrastructure, sufficient qualified professionals and fair procurement policies.
- Cancer care outcomes can improve rapidly through enhanced collaboration among policymakers, industry, healthcare professionals, and patient advocacy groups, with ECGP as a key enabler.
Read the complete recommendations here.
Contact person:
Matias Olsen,
Senior Manager, Public Affairs & Policy
E: olsen@eucope.org
T: +32 (0) 2 842 69 87
Leave a Reply